This is a working overview of trans-3-hexenoyl, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
==== Single-drug formulations ==== Adapalene (CD-271; Differin) – retinoid (retinoic acid receptor agonist) Azelaic acid (BAY39-6251; Finacea; Skinoren) – undefined mechanism of action Benzoyl peroxide (Bepio; M6050; M605101) – undefined mechanism of action Clascoterone (Breezula; Winlevi; CB-03-01; cortexolone 17α-propionate) – antiandrogen (androgen receptor antagonist) Clindamycin (ResiDerm A; Zindaclin) – lincosamide antibiotic Dapsone topical (Aczone; Atrisone) – sulfone antibiotic Doxycycline hyclate (Acticlate; Monodox; AQ101) – tetracycline antibiotic Isotretinoin (Absorica; Accutane; CIP-isotretinoin; Epuris; Lisacne-CIP) – retinoid (retinoic acid receptor agonist) Minocycline (DFD-10; DFD-29; Emrosi; Minolira) – tetracycline antibiotic Minocycline foam (Amzeeq; FMX-102; FMX-103; FMX-101; FXFM-244; Zilxi) – tetracycline antibiotic Nadifloxacin topical – fluoroquinolone antibiotic Ozenoxacin (Dubine; GF-001001-00; M-5120; M-512101; M-512102; Ozadub; Ozanex; T-3912; Xepi; Zebiax) – quinolone antibiotic Sarecycline (Seysara; P-0005672; WC-3035) – narrow-spectrum tetracycline antibiotic Solubilised benzoyl peroxide (CLENZIderm M.D.; SoluCLENZ Rx Gel) – undefined mechanism of action Tazarotene topical (AGN-190299; Avage; Fabior; Suretin; Tazorac; Zorac) – retinoid (retinoic acid receptor agonist) Tretinoin (Acnisdin Retinoico; All-trans retinoic acid; Arotinoid; Avita; Dermojuventus; Loderm Retinoico; NSC 122758; Retinoic acid; Retirides; Vesanoid; Vitamin A acid; Vitamin-A Acid; Vitanol) – retinoid (retinoic acid receptor agonist) Tretinoin lotion (Altreno; IDP-121) – retinoid (retinoic acid receptor agonist) Trifarotene (Aklief; CD-5789) – retinoid acid receptor gamma (RAR-γ) agonist
Plasma protein binding refers to the degree to which medications attach to blood proteins within the blood plasma. A drug's efficacy may be affected by the degree to which it binds. The less bound a drug is, the more efficiently it can traverse or diffuse through cell membranes. Common blood proteins that drugs bind to are human serum albumin, lipoprotein, glycoprotein, and α, β‚ and γ globulins.
The lungs are especially sensitive and prone to damage, thus to avoid collateral damage to type I and type II pneumocytes, alveolar macrophages are kept in a quiescent state, producing little inflammatory cytokines and displaying little phagocytic activity, as evidenced by downregulated expression of the phagocytic receptor Macrophage 1 antigen (Mac-1). AMs actively suppress the induction of two of the immunity systems of the body: the adaptive immunity and humoral immunity. The adaptive immunity is suppressed through AM's effects on interstitial dendritic cells, B-cells and T-cells, as these cells are less selective of what they destroy, and often cause unnecessary damage to normal cells. To prevent uncontrolled inflammation in the lower respiratory tract, alveolar macrophages secrete nitric oxide, prostaglandins, interleukin-4 and -10(IL-4, IL-10), and transforming growth factor-β (TGF-β).
==== Antioxidant activity ==== Honokiol has also been proposed as an antioxidant. The compound protects against lipid peroxidation by interfering with ROS production and migration. Accumulation of ROS extracellularly causes macromolecular damage while intracellular accumulation may induce cytokine activation.
=== Usage === Humans can scan for eyeshine to detect and identify the species of animals in the dark and deploy search dogs and search horses at night. The color corresponds approximately to the type of tapetum lucidum, with some variation between species. It has been speculated that some flashlight fish may use eyeshine both to detect and to communicate with other flashlight fish. American scientist Nathan H. Lents has proposed that the tapetum lucidum evolved in vertebrates, but not in cephalopods, which have a very similar eye, because of the backwards-facing nature of vertebrate photoreceptors. The tapetum boosts photosensitivity under conditions of low illumination, thus compensating for the suboptimal design of the vertebrate retina.
Sources: en.wikipedia.org
Once the substrate is bound and oriented to the active site, catalysis can begin. The residues of the catalytic site are typically very close to the binding site, and some residues can have dual-roles in both binding and catalysis. Catalytic residues of the site interact with the substrate to lower the activation energy of a reaction and thereby make it proceed faster. They do this by a number of different mechanisms including the approximation of the reactants, nucleophilic/electrophilic catalysis and acid/base catalysis. These mechanisms will be explained below.
=== Pharmacokinetics === The bioavailability of lemborexant is good and is at least 87%. The time to peak levels of lemborexant is 1 to 3 hours. A high-fat and high-calorie meal has been found to delay the time to peak levels by 2 hours. Its plasma protein binding in vitro is 94%. Lemborexant is metabolized primarily by CYP3A4 and to a lesser extent by CYP3A5. The "effective" half-life of lemborexant is 17 to 19 hours while its terminal elimination half-life is 55 hours. The medication is excreted in feces (57%) and to a lesser extent urine (29%).
== Medical uses == In the United States, dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In the European Union, it is indicated in adults aged 18 years and older with type 2 diabetes:
=== Preservation in a resin pour === A resin pour preservation allows for flowers like roses to be preserved in a clear transparent mould, making this method a great choice for ornamental preservation of flowers. Two separate resin elements are mixed in equal proportions and poured into a silicone mould, often in an ice cube shape, with the flower inserted. With each pour, a heat gun is used to remove air bubbles that form at the surface of the pour. Those attempting a resin pour preservation are recommended to wear a respirator and gloves as a resin pour can give off fumes and also a considerable amount of heat. The preservation of real dried flowers can also be done within a bezel-based structure poured with resin.
Itching Nausea Sedation Respiratory depression - can be potentially life-threatening However, since viminol is supplied as a racemic mixture of agonist and antagonist isomers, the abuse potential and respiratory depression tends to be less than that of μ-opioid full agonist drugs. Drug dependence may occur.
Sources: en.wikipedia.org
== Mechanism of activation == Opioid receptors are a type of G protein–coupled receptor (GPCR). These receptors are distributed throughout the central nervous system and within the peripheral tissue of neural and non-neural origin. They are also located in high concentrations in the periaqueductal grey, locus coeruleus, and the rostral ventromedial medulla. The receptors consist of an extracellular amino acid N-terminus, seven trans-membrane helical loops, three extracellular loops, three intracellular loops, and an intracellular carboxyl C-terminus. Three GPCR extracellular loops provide a compartment where signalling molecules can attach to generate a response. Heterotrimeric G protein contain three different sub-units, which include an alpha (α) subunit, a beta (β) subunit, and a gamma (γ) sub-unit. The gamma and beta sub-units are permanently bound together, producing a single Gβγ sub-unit. Heterotrimeric G proteins act as 'molecular switches', which play a key role in signal transduction, because they relay information from activated receptors to appropriate effector proteins. All G protein α sub-units contain palmitate, which is a 16-carbon saturated fatty acid, that is attached near the N-terminus through a labile, reversible thioester linkage to a cysteine amino acid. It is this palmitoylation that allows the G protein to interact with membrane phospholipids due to the hydrophobic nature of the alpha sub-units. The gamma sub-unit is also lipid modified and can attach to the plasma membrane as well.
=== Terpolymers === Terpolymers of PVDF are the most promising one in terms of electromechanically induced strain. The most commonly used PVDF-based terpolymers are P(VDF-TrFE-CTFE) and P(VDF-TrFE-CFE). This relaxor-based ferroelectric terpolymer is produced by random incorporation of the bulky third monomer (chlorotrifluoroethylene, CTFE) into the polymer chain of P(VDF-TrFE) copolymer (which is ferroelectric in nature). This random incorporation of CTFE in P(VDF-TrFE) copolymer disrupts the long-range ordering of the ferroelectric polar phase, resulting in the formation of nano-polar domains. When an electric field is applied, the disordered nano-polar domains change their conformation to all-trans conformation, which leads to large electrostrictive strain and a high room-temperature dielectric constant of ~50.
Specialist Physiotherapist in Parkinson's Disease, University Hospitals of Derby and Burton NHS Foundation Trust. For services to Physiotherapy. Brenda Anne Lines. Chair, Big Local DY10. For services to the community in Kidderminster, Worcestershire. Richard John Linley. Lately Senior Inspector of Courses, British Horseracing Authority. For services to Horse Racing. Antony Lishak. Chief Executive, Learning from the Righteous. For services to Holocaust Education. Sharon Louise Livermore. Founder, Domestic Abuse Education and Director, Kameo Recruitment. For services to the Victims of Domestic Abuse. Shalom Ijeoma Lloyd. Director, Naturally Tiwa Skincare. For services to International Trade and to Women in Business. Dr. Leonard Malcolm Lofts. Patron and Lately Chief Executive, Northam Care Trust. For services to People with Disabilities in Devon. Joanne Elizabeth Loftus. Lately Civil Secretary, Ministry of Defence. For services to Defence. Louise Long. Chief Executive, Inverclyde Council. For services to Local Government and to the community in Inverclyde, Renfrewshire. Maria Victoria Rodriguez Lopez. Head of Partnerships, Scottish Government. For services to Minority Ethnic Communities in Scotland during Covid-19. Paul John Lord. Director of Sport and Senior Leader, Westcroft Special School. For services to Children and Young People with Special Educational Needs. Andrew McLauchlan Lothian. Founder and Director, Insights Learning and Development. For services to Personal and Professional Development. Dickon Rutherford Love. For services to Bell-Ringing in London and Kent.
=== Comparison with analogues === Hydrogen peroxide has several structural analogues with HmX−XHn bonding arrangements (water also shown for comparison). It has the highest (theoretical) boiling point of this series (X = O, S, N, P). Its melting point is also fairly high, being comparable to that of hydrazine and water, with only hydroxylamine crystallising significantly more readily, indicative of particularly strong hydrogen bonding. Diphosphane and hydrogen disulfide exhibit only weak hydrogen bonding and have little chemical similarity to hydrogen peroxide. Structurally, the analogues all adopt similar skewed structures, due to repulsion between adjacent lone pairs.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.